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Abstract: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the central nervous 
system. It affects approximately 400,000 people in the United States and onset is usually during young adulthood. There 
are four clinical forms of MS, of which relapsing remitting type is the most common. As the etiology of MS is unknown, 
finding a cure will remain challenging. The main mechanism of injury appears to be inflammation and 8 agents are now 
FDA approved to help control MS.  These agents for relapsing forms of MS target different parts of the immune system, 
with the end goal of decreasing and avoiding further inflammation. No agents are FDA approved for the primary 
progressive version of MS. FDA approved agents include four preparations of interferon  (Avonex, Rebif, Betaseron and 
Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri) and fingolimod (Gilenya). 
There are several drug undergoing phase II and III trials. The heterogeneity of the MS disease process, individual patient 
response, and medication toxicities continue to challenge the treating physician.   
Keywords: Multiple sclerosis, pathogenesis, immune response, interferon-beta, glatiramer acetate.  
INTRODUCTION 
  Multiple sclerosis (MS) is a chronic inflammatory auto-
immune demyelinating disease of the central nervous sys-
tem. Multiple sclerosis affects approximately 400,000 people 
in the United States alone, most of them being young adults 
[1]. It expresses itself in four clinical forms: relapsing remit-
ting MS (RRMS), secondary progressive MS (SPMS), pri-
mary progressive MS (PPMS), and progressive relapsing 
MD (PRMS) (See Table 1). Approximately 87% of patients 
present with RRMS, characterized by acute attacks (relapses) 
followed by partial or full recovery (remission) [2]. Patients 
can manifest with a heterogeneous group of symptoms in-
cluding changes in vision (unilateral visual loss, diplopia), 
weakness, dyscoordination, sensory loss or distortions, or 
changes in bowel and bladder function. Less diagnostic but 
also disabling symptoms include cognitive change, fatigue, 
and mood disturbance. Progression of disease may eventu-
ally lead to severe disability. Many medications and other 
measures may be used to ameliorate MS symptoms. The 
availability of disease modifying therapies has revolution-
ized the care of patients with the relapsing forms of this dis-
ease. These medications help control the underlying disease 
process, probably by decreasing immune mediated inflam-
mation. They do not cure the disease or reverse the damage 
that has occurred with prior events. In general the effects of 
these agents appear more potent when they are given to pa-
tients before more severe widespread damage and disability 
have occurred. As the number of FDA-approved therapies 
continues to increase and other investigational and off label 
uses expands, it is helpful to review both the pathogenesis of 
MS and the effects of the pharmacologic agents.  
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PATHOGENESIS OF MULTIPLE SCLEROSIS 
  Inflammation of central nervous system is the primary 
cause of damage in MS. The specific elements that start this 
inflammation are still unknown. Studies have suggested that 
genetic, environmental and infectious agents may be among 
the factors influencing the development of MS. Many im-
munological studies have been done on the animal model for 
human MS known as the experimental autoimmune encepha-
lomyelitis (EAE). Based on this model and observations of 
MS in humans, roles of several immunological pathways 
involved in MS are being explored. To understand these 
pathways it is important to first understand some basic points 
of the immune system in MS. While we have learned much 
about the immune system by the study of EAE, our lack of 
understanding of the differences between EAE and MS as 
well as the complexity of MS (and likely different immu-
nologic subtypes of MS) must be kept in mind when review-
ing experimental and immunologic data [3]. 
  There are two general types of immune response. These 
are the innate and adaptive immune responses. The innate 
immune response is initiated by microbial products that acti-
vate specific receptors, mainly toll-like receptors (TLRs) in 
an antigen nonspecific manner. Activation of specific subsets 
of TLR is done by pathogen-associated molecules that are 
unique for different groups of pathogens. Binding of these 
molecules to TLRs results in the production of cytokines that 
modulate the adaptive immune response [4]. The innate sys-
tem plays a role both in the initiation and progression of MS 
by influencing the effector function of T and B cells [4]. For 
example, when activated through TLRs, dendritic cells 
(DCs) become semi- mature and induce regulatory T cells to 
produce inhibitory cytokines such as IL-10 or TGF- [5]. As 
the dendritic cells continue to mature, they start to polarize 
CD4
+ T cells to differentiate into either Th1, Th2 phenotypes 
or Th17 phenotypes. When T cells differentiate to a Th1 
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EAE model suggest that glatiramer acetate may induce type 
II monocytes which promote Th2 cell production and devel-
opment of regulatory T cells, which then decrease inflamma-
tion [6].  
  The adaptive response is initiated by the presentation of a 
specific antigen to T lymphocytes by antigen presenting cells 
(APCs). These antigen presenting cells include B cells, den-
dritic cells, microglia and macrophages. The interaction be-
tween the APC and T cell is a chief component to initiate the 
adaptive immune response. Several types of T cells includ-
ing CD4
+
 and CD8
+
 phenotype can be activated by APCs. 
Th1, Th2 cells and Th17 are CD4
+
 effector cells that are 
polarized in response to exposure to specific interleukins. 
Once polarized to Th1, Th2 or Th17, these effector T cells 
secrete specific cytokines. The cytokines produced by Th1 
cells are proinflammatory cytokines such as interferon 
gamma, whereas Th2 cells secrete anti-inflammatory cytoki-
nes such as IL-4 and IL-13. Th17 is a newly recognized 
CD4
+
 T cell subset that produces IL-17, IL-21, IL-22 and 
IL-26. Like Th1 cells, Th17 cells promote inflammation in 
MS. IL-17 receptors are seen in acute and chronic MS 
plaques. Moreover, studies in IL-17 deficient mice show 
reduction of clinical severity [7]. Th1 cells and Th17 cells 
migrate to the central nervous system after being primed in 
the periphery. Subsequent demyelination and axonal loss is 
then seen [4]. 
  Regulatory T cells (T reg) are another CD4
+ T cell type 
involved in the pathogenesis of MS. The role of T reg cells is 
to regulate effector Th1, Th2 and Th17 cells. The number of 
T reg cells is the same between MS patients and controls, 
however patients with MS have reduced T reg function [8]. 
IFN- enhances CD4+ regulatory T-cell function [9]. An-
other study showed that glatiramer acetate can also increase 
regulatory T cell function by increasing the expression of 
naïve CD4
+CD25
+FoxP3
+CD31
+ T cells [10]. 
  Besides the involvement of CD4
+ T cells in MS patho-
genesis, studies have shown that CD8
+ T cells are present in 
MS lesions and may have regulatory function in the progres-
sion of disease. CD8
+ cells mediate suppression of CD4
+ T 
cell proliferation through the secretion of perforin, which is 
cytotoxic on CD4
+ T cells, leading to their inactivation [5]. 
Also, CD8 
+cells kill glial cells, leaving axons exposed [5]. 
Moreover, CD8
+ T cells transect axons, promote vascular 
permeability and activate oligodendrocyte death [5]. All of 
these events are seen in MS lesions.  
  In addition to T cells, B cells and their products are in-
volved in the pathogenesis of MS. It has long been recog-
nized that B cells become plasma cells that make antibodies. 
The presence of these polyclonal antibodies in the cerebro-
spinal fluid of MS patients is known as oligoclonal bands. 
The target of these antibodies is not yet known. Besides the 
production of antibodies, B cells are now known to produce 
proinflammatory (lymphotoxin, TNF-alpha produced by 
memory B cells) and anti-inflammatory (IL-10) cytokines 
(produced by naïve B cells) [11]. CD20, the target of mono-
clonal antibody rituximab, is present throughout the matura-
tion of B cells, however it is absent on plasma cells. Moreo-
ver, Magliozzi et al. [12] showed that B cell follicles are 
found in the brains of MS patients. These follicles express 
CD20. Studies have shown the benefits of depletion of 
CD20
+ B cells after rituximab infusion, thus inhibiting B cell 
antigen presentation functions [13].  
  Genetic factors influence MS pathogenesis susceptibility. 
Studies of families and twin have shown a 40-fold increased 
susceptibility among first degree relatives of MS patients, 
suggesting a genetic basis. The HLA locus on chromosome 
6p21 which contains the DR antigens has been linked to MS 
susceptibility. An HLA-DRB1*1501-DQB1*0602 haplotype 
(DR2) has been repeatedly demonstrated in high-risk popula-
tions of Northern European descent. Additional susceptibil-
ity loci include chromosomes 10p15, 5p13, and 1p36 [14]. 
  Environmental factors, such as exposure to infectious 
agents as well as sunlight exposure/vitamin D are felt to ac-
count for changing risk of MS when a person migrates from 
one risk area to another before age 15 years old [15]. Many 
recent studies suggesting an infectious etiology have been 
conducted in children and adolescents with MS. Among the 
pathogens possibly involved are human herpes virus type 6, 
Epstein Barr virus, and mycoplasma pneumoniae [16]. It is 
speculated that one way for pathogens to produce MS would 
be by molecular mimicry. The pathogens may have peptides 
with direct sequence homologies with myelin components. 
Also, it is clear that common viral infections such as upper 
respiratory tract infections and bacterial urinary tract infec-
tions may trigger MS relapses. The mechanism by which this 
happens is still unknown. Multiple studies of sunlight expo-
Table 1.  Types of Multiple Sclerosis 
Type Disease  Course 
Relapsing/Remitting Multiple Sclerosis (RRMS)  Most common type, accounts for approximate 85% of cases. Characterized by discrete attacks that 
evolve over days to weeks followed by some decree of recovery over weeks to months. In between 
attacks, the patient has no worsening neurological function.  
Secondary Progressive Multiple Sclerosis (SPMS)  Characterized by initial relapses, followed by gradual neurological deterioration not associated  
with acute attacks.  
Primary Progressive Multiple Sclerosis (PPMS)  Characterized by steady functional decline from the onset of the disease. No relapses ever.  
Progressive Relapsing Multiple Sclerosis (PRMS)  Characterized by steady functional decline from onset of the disease with later superimposed acute 
attacks. PRMS and PPMS cannot be distinguished during early stages, until the relapses occur Multiple Sclerosis: Pathogenesis and Treatment  Current Neuropharmacology, 2011, Vol. 9, No. 3    411 
sure and vitamin D levels suggest a potential protective   
effect of early life sun exposure or vitamin D consumption 
[17]. 
TREATMENT OF MULTIPLE SCLEROSIS 
  On its website the National MS society listed more than 
136 ongoing clinical trials testing different treatments for 
multiple sclerosis [18]. There are currently 8 FDA approved 
agents for relapsing forms of MS. No agents are FDA   
approved for the primary progressive version of MS (See 
Table  2). FDA approved agents include four preparations   
of interferon-beta (Avonex, Rebif, Betaseron and Extavia), 
glatiramer acetate (Copaxone), mitoxantrone (Novantrone), 
and natalizumab (Tysabri) and the recently approved first 
oral medication fingolimod (Gilenya) [18] (See Table 3). 
Many other immunologically active agents are used off label 
and others are nearing study completion and FDA applica-
tion. The differing types and durations of immunologic ef-
fects of these agents will increase the complexity and likely 
risks of future MS care.  
Interferon-Beta 
  Interferon beta (IFN-beta) was first approved by the FDA 
for MS treatment on 1993. It has been shown to reduce re-
Table 2.  Overview Treatment for Different Types of Multiple Sclerosis 
Type of Multiple Sclerosis  Treatments 
Non-symptomatic Multiple Sclerosis  Interferon beta -1a and 1b, glatiramer acetate, intravenous immunoglobulin 
Relapsing Remitting Multiple Sclerosis and Secondary 
Progressive Multiple Sclerosis 
Interferon beta-1a and 1b, glatiramer acetate, natalizumab, intravenous immunoglobulin, pulse 
methylprednisolone (for acute relapses).  
If poor response: mitoxantrone, cyclosphosphamide, mycophenolate, azathioprine, methotrexate, 
methylprednisolone, intravenous immunoglobulin, cyclosporine  
Primary Progressive Multiple Sclerosis and Progressive 
Relapsing Multiple Sclerosis 
No specific treatment has been shown to be effective.  
Ineffective agents: interferon beta, mitoxantrone, rituximab 
 
Table 3.  Multiple Sclerosis Drug Treatment Dosages 
Drug Dosage  Examples 
Interferon beta   
   Interferon beta-1a (Rebif)  22 mcg or 44 mcg subcutaneous three times a week (initial titration) 
   Interferon beta-1a (Avonex)  30 mcg intramuscular once a week (initial titration) 
   Interferon beta-1b (Betaseron & Extavia)  250 mcg subcutaneous every other day (initial titration)  
Glatiramer acetate (Copaxone)  20 mg subcutaneous once a day 
  Fingolimod (FTY720;Gilenya)   0.5 mg orally once a day 
Monoclonal Antibodies   
    Natalizumab (Tysabri)  300 mg intravenous every four weeks 
   *Rituximab (Rituxan)   1000 mg dosed four times a year 
Cytotoxic and Other Agents   
  Mitoxantrone  5 to 12 mg/m
2 intravenous every three months 
  *Cyclophosphamide  Wide dose range 
  *Azathioprine  2 mg/kg oral every day 
  *Methotrexate  7.5 mg to 20 mg once per week 
  *Mycophenolate mofetil  500 to 1000 mg oral twice a day 
*Methylprednisolone (as disease modifying therapy)  500 to 1000 mg intravenous daily pulses, monthly to every 4 months  
*Intravenous Immunoglobulin   0.2 to 1 g/kg intravenous every month  
FDA Application Pending Medications   
 *Cladribine  3.5 to 5.25 mg/kg intermittent pulses 
“*””: off label or pending FDA approval. 412    Current Neuropharmacology, 2011, Vol. 9, No. 3  Loma and Heyman 
lapse rate, decrease disability progression, and MRI evidence 
of disease activity [19]. The clinical efficacy of IFN-beta is 
greater in RRMS than in SPMS. The exact of mechanism of 
how IFN-beta affects MS is uncertain, however several po-
tential pathways have been postulated. Among these mecha-
nisms, inhibition of T cell activation and proliferation as well 
as reduction in matrix metalloproteinase activity may be im-
portant. IFN-beta has numerous other immunologic effects. 
It reduces the production of proinflammatory cytokines and 
induces the production of anti-inflammatory cytokines by 
increasing suppressor T cell activity [20].  
  There are four IFN-beta products available on the market. 
Interferon beta-1b products (Betaseron and the identical Ex-
tavia) are recombinantly produced by Escherichia coli bacte-
ria. It differs from the IFN-beta made endogenously in hu-
mans as it has a single amino acid substitution and is not 
glycosylated. Interferon beta-1b is administered via subcuta-
neous injection every other day and is titrated to a target 
dose over 6 weeks. Interferon beta-1a (Avonex and Rebif) are 
recombinant peptides produced in Chinese hamster ovary 
cells and are identical to natural human interferon-beta. The 
Avonex formulation is given intramuscularly once a week 
and the Rebif formulation is given subcutaneously 3 times 
per week. All four formulations bind to the same type I inter-
feron receptor expressed on human cells. Neutralizing anti-
bodies can negate the benefits of these agents [21]. The rate 
of neutralizing antibody formation varies between the differ-
ent interferon beta products, with interferon beta 1-b having 
the highest rate and the once weekly intramuscular interferon 
beta 1-a having the lowest neutralizing antibody induction 
rate. A review of the biologic effects of neutralizing antibod-
ies and a suggested clinical approach is discussed in Polman 
et al. 2010 [22]. 
  The most common adverse effects of interferon beta are 
injection site inflammation, headache, and flu like symptoms 
(fever, myalgia and rigors), fatigue and possibly depression. 
Other adverse reactions include lymphopenia, thrombocy-
topenia, and elevated liver transaminase levels [19,23]. Prior 
to starting IFN-beta therapy and periodically thereafter pa-
tients should have a complete blood cell count and hepatic 
function tests [23].  
Glatiramer Acetate 
  Glatiramer acetate (GA), formerly known as copolymer 
1, is a random polymer of glutamic acid, lysine, alanine and 
tyrosine, the most common amino acids in myelin basic pro-
tein. The exact mechanism of action is not clear yet Racke et 
al. [24)] showed that GA inhibits response of various anti-
gen-specific murine T cell hybridomas. It also blunts human 
myelin basic protein-specific T cell lines from lysing targets 
in the presence of three human leukocyte antigen-DR types 
associated with MS. Further studies have shown that GA 
increases cytokine levels such as IL-10, TNF-alpha, and IL-
4, thus altering the cytokine population to a more regulatory 
type [24]. It also increases the expression of Foxp3 in CD4
+ 
CD25
+T regulatory cells, thus increasing anti-inflammatory 
action. Therefore it appears that GA shifts the GA-reactive 
lymphocyte population from a proinflammatory Th1 state to 
an anti-inflammatory Th2 state. Further, GA has been shown 
to act upon CD8
+D T cells by correcting their regulatory 
deficit [25]. 
  There is one formulation of GA marketed as Copaxone, 
and it is currently approved for the treatment of RRMS. It 
has proven effects on exacerbation rate and MRI clinical 
assessment. It is given subcutaneously on a daily basis. Side 
effects may include erythema, induration, or lipoatrophy at 
the sites of injections. An immediate post-injection systemic 
reaction can occur seconds to minutes after injection. The 
symptoms consist of chest tightness, dyspnea, tachycardia, 
flushing and palpitations. This reaction lasts 10-20 minutes, 
and has not been determined to be dangerous to patients 
[24]. There are no specific blood tests that need to be moni-
tored while the patient is taking GA.  
Monoclonal Antibodies  
  Monoclonal antibodies (mAbs) have been studied since 
the 1980's. There are three different types of monoclonal 
antibodies differentiated by their structural similarity to hu-
man antibody structure. Humanized antibodies consist of 
more than 90% human components with the balance from 
the original murine structure. These antibodies include natal-
izumab, alemtuzumab and daclizumab. Chimeric antibodies 
are at least 66% human structure and structure, and rituxi-
mab belongs to this class of antibodies. Fully human anti-
bodies have no murine structural components [26]. Each 
mAb is developed to bind to a specific target molecule. mAb 
mechanism of action depends on the distribution of the tar-
geted molecule, efficacy of the antibody in reaching the tar-
get, the interaction between the antibody and target, and the 
effector functions of the interaction. The mAbs may interact 
with their target by binding, blocking or signaling [26]. The 
type of interaction depends on its Fab activity. A binding 
mAb can mark a target for destruction through is effector 
function or through conjugation of the mAb to a toxin. An-
other mechanism is by blocking the epitope needed for 
ligand interaction, thus preventing signaling. Both natalizu-
mab and daclizumab are blocking mAbs. Monoclonal anti-
bodies can also mediate cytotoxic immune responses and 
destroy targeted cells. This effector function depends on the 
Fc domain of the antibody. To date the four monoclonal an-
tibodies most studied for MS are natalizumab, daclizumab, 
alemtuzumab and rituximab [26].  
Natalizumab 
 Natalizumab  (Tysabri) is a humanized monoclonal anti-
body with an IgG4 framework. It was specifically designed 
for the treatment of MS and was FDA approved on 2004. It 
was temporarily withdrawn from the market in 2005 after 
several cases of fatal progressive multifocal leukoencephalo-
pathy were reported in patients treated with natalizumab. It 
was reapproved on 2006 as a monotherapy for the treatment 
of RRMS [27]. Its target molecule is CD49, the 4 subunit 
of very late antigen-4 (VLA-4) receptor. VLA-4 interacts 
with vascular cell adhesion molecule-1 so that immune cells 
can migrate through the blood brain barrier. By binding to 
CD49, natalizumab prevents the adhesion between the endo-
thelial cell and the immune cell, thus migration of leukocytes 
into the central nervous system is blocked [27]. This agent 
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and MRI activity. The risk of PML requires clinical surveil-
lance for infection with JC virus while treated with this 
agent. 
Alemtuzumab 
 Alemtuzumab  (Campath-1H) is a humanized antibody 
that was initially approved for the treatment of B-cell 
chronic lymphocytic leukemia. It remains an investigational 
agent for MS. Its target molecule is CD52, a glycoprotein 
expressed widely throughout on T and B cells, natural killer 
cells, dendritic cells, monocytes, macrophages and granulo-
cytes with the exemption of neutrophils [28]. Alemtuzumab 
causes a complete depletion of CD52 bearing cells. It de-
pletes cells that mediate Ab-dependent cellular cytotoxicity, 
i.e. natural killer cells. Studies have shown that the depletion 
of these immune cells is associated with a decrease in con-
trast enhancing lesions in MS, thus suggesting stabilization 
of the blood brain barrier [28]. A phase II clinical trial com-
paring the efficacy of alemtuzumab versus interferon beta-1a 
in patients with RRMS showed a 71% reduction in the rate 
of sustained accumulation of disability and 74% reduction of 
relapse rate in patients treated with alemtuzumab compared 
to patients treated with interferon beta-1a [29]. Despite its 
efficacy, a number of potentially dangerous adverse effects 
and complications may occur in patients treated with alemtu-
zumab and limit its use. Such side effects include idiopathic 
thrombocytopenic purpura, Graves' disease and Goodpasture 
syndrome, all which are Ab-mediated autoimmune diseases 
[29].  
Rituximab 
 Rituximab  (Rituxan) is a chimeric murine/human IgG1 
monoclonal antibody. Its target is CD20, an antigen pro-
duced only on mature B cells and not on the Ab-producing 
plasma cells. This monoclonal antibody is FDA approved for 
the treatment of rheumatoid arthritis and B cell lymphoma 
and it remains an investigational agent for treatment of MS. 
Rituximab's primary mechanism of action is a complete de-
pletion of B cells [30]. This depletion of B cells occurs 
within 2 weeks of initiating treatment and can last for more 
than 6 months. The exact mechanism of benefit with rituxi-
mab treatment remains uncertain. Cases of PML have oc-
curred after the use of this agent as well [31].  
Daclizumab 
 Daclizumab  (Zenapax) is a humanized monoclonal anti-
body with an IgG1 framework. It was used initially for the 
prevention of allogenic tissue transplantation. Its target 
molecule is CD25, the IL-2 binding epitope of the -chain of 
the IL-2 receptor [32]. IL-2 plays an important role both in 
the regulation of lymphocyte expansion and contraction.  
CYTOTOXIC AND OTHER AGENTS 
  Clinicians may use a variety of cytotoxic agents for con-
trol of MS despite only mitoxantrone having FDA approval 
for MS. Off label use of other cytotoxic agents is based on 
smaller studies, and agents most frequently used include 
cyclophosphamide, azathioprine, methotrexate, and myco-
phenolate mofetil [33]. The main mechanism of action of all 
these agents appears to be a more broad immunosuppressive 
action and these agents not unexpectedly may increase the 
risk of infections and neoplasia. Other immunomodulatory 
agents used include intravenous immunoglobulin and corti-
costeroids. Overall the risks of cytotoxic drugs for treatment 
of multiple sclerosis are proportional to the length and inten-
sity of immunosuppression. Data regarding their efficacy as 
monotherapy or in combination with FDA approved immu-
nomodulatory is still limited. Thus, cytotoxic drugs are not 
the first line agents used in the treatment of MS.  
Mitoxantrone 
 Mitoxantrone  (Novantrone) is a synthetic anthracenedi-
one that intercalates into DNA. It causes cross-linking and 
strand breaks and inhibits topoisomerase II, thus interfering 
with DNA repair. Besides causing generalized immunosup-
pression, mitoxantrone inhibits monocyte and lymphocyte 
migration, induces apoptosis of dendritic cells, decreases the 
secretion of proinflammatory cytokines such as tumor necro-
sis factor, interleukin-2 and interferon-g [33]. It also inhibits 
B cell function, increases T cell suppressor function and in-
hibits macrophage mediated myelin degradation. Mitoxan-
trone was approved by the FDA on 2000 for SPMS and 
worsening RRMS [33]. It can be given intravenously every 3 
months. Side effects include bone marrow suppression, mild 
alopecia, nausea and possible transient bluish discoloration 
of the sclera and urine [34]. Risks also include vacuolar   
cardiomyopathy, treatment related leukemia, and sterility/ 
teratogenesis [34].  
Cyclophosphamide 
  Cyclophosphamide is a synthetic chemical agent related 
to nitrogen mustards. It is transformed in the liver to active 
alkylating metabolites to then cross link DNA. In addition to 
generalized suppression, cyclophosphamide increases Th2 
cells and targets selectively CD45
+/CD4
+/RA T cells [33]. Its 
side effects include alopecia, nausea, vomiting, amenorrhea, 
myelosuppression, hemorrhagic cystitis, bladder carcinoma 
and other secondary cancers, and sterility/teratogenesis [35]. 
Currently, cyclosphosphamide is used off label for RRMS.  
Azathioprine 
  Azathioprine is a purine antagonist that blocks the de 
novo pathway of purine synthesis, thus depleting the produc-
tion of lymphocytes that lack a salvage pathway. Azathio-
prine is sensitive to inactivation by thiopurine S-methyltrans- 
ferase polymorphisms [33]. Besides immunosuppression, the 
side effects include gastrointestinal and hepatic toxicity.  
Methotrexate  
  Methotrexate inhibits the synthesis of DNA, RNA and 
protein by inhibiting dihydrofolic acid reductase, which is 
necessary for the synthesis of thymidylate. Through this re-
action, lymphocyte production is inhibited, thus reducing 
inflammation. Side effects include myelosuppression, gastro-
intestinal toxicity, pneumonitis, and hepatic fibrosis. This 
agent is most often used orally in lower doses but has also 
been tried in high dose intravenous regimens. The Cochrane 
study done by Gray et al. [36] showed that methotrexate had 
a non-significant trend in reduction of sustained EDSS pro-
gression or number of relapses in progressive MS. Currently 
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Mycophenolate Mofetil 
  Mycophenolate mofetil causes lymphocyte depletion, 
inhibits T cell activation and B cell function, and inhibits B 
and T cell migration through the blood brain barrier. Its 
mechanism involves the inhibition of inosine monophos-
phate dehydrogenase activity, which is needed for purine 
synthesis [33]. Side effects include leukopenia, anemia, 
headaches and diarrhea. 
Intravenous Immunoglobulin 
  Treatment with intravenous immunoglobulin (IVIG) has 
been reported as beneficial for treatment of patients with 
RRMS. A meta-analysis study done by Sorensen et al. [37] 
showed that patients treated with monthly doses of IVIG had 
significant decrease on relapse rate, improved disability 
scores and decrease deterioration. The dose ranged widely 
from 0.2 mg/kg to 2 g/kg. No ideal dosage was determined. 
Another study done by Fazekas et al. [38] showed that pa-
tients treated with IVIG (0.2-0.4 mg/kg) did not show sig-
nificant improvement or relapse rate or disability compared 
to patients with placebo. The number of patients in each arm 
of this study was relatively small however and as the data on 
IVIG remains ambiguous it is not usually used as a first line 
treatment. It might be considered in patients who are preg-
nant, [39] cannot tolerate FDA approved therapies, or in pa-
tients with frequent infections.  
Corticosteroids 
  Corticosteroids inhibit lymphocyte proliferation and the 
synthesis of most pro-inflammatory cytokines. Because of 
their potent anti-inflammatory effects, corticosteroids have 
been used to treat MS for the last 50 years. Today corticos-
teroids are standard treatment for patients with acute re-
lapses, however it is not yet clear if they are as efficacious as 
a long term treatment. Ciconne et al. [40] did a Cochrane 
review to study the long term effect of corticosteroids in pa-
tients with all types of MS. The analysis showed that overall 
there was no clear evidence that corticosteroids slowed or 
reversed disease progression. One study used periodic high 
dose methylprednisolone and showed a significant reduction 
in the risk of disability progression and brain atrophy at 5 
years in patients with RRMS [41]. Because of the heteroge-
neity of the study results, it was concluded that there was not 
enough evidence to prove corticosteroids prevent disease 
progression. The acute and long term risks of corticosteroids 
are well known and may be serious.  
Emerging Treatments 
  To date all the FDA approved treatments for MS are 
given via injection or infusion. A significant amount of re-
search has been done to develop oral agents in the hope of 
patient compliance and tolerability. Fingolimod is a new oral 
medication with a recently approved FDA application and is 
awaiting wider use [42]. A recent placebo controlled trial 
was done using cladribine in patients with RRMS [43]. On-
going clinical trials are being conducted with three other oral 
agents: laquinimod, fumarate (BG00012) and teriflunomide 
[44].  
Fingolimod 
  Fingolimod (FTY720) is a structural analogue of sphin-
gosine. It targets receptors of sphingosine-1-phosphate 
(S1P). S1P is an important signaling lipid involved in the 
migration of lymphocytes from secondary lymphoid organs 
to the periphery. Studies have shown that with higher density 
of S1P, there are more lymphocytes released from secondary 
lymphoid organs [44]. Other studies have shown that 
FTY720 inhibits mature dendritic cells migration to secon-
dary lymphoid organs [45]. FTY720 also improves myelina-
tion in animal models of EAE. Recently, a double blind 
study done by Cohen et al. [42] compared the efficacy of 
oral fingolimod (0.5-1.25 mg) to intramuscular interferon 
beta-1a in patients with RRMS. A total of 1153 patients were 
studied. The results showed that patients treated with fingo-
limod had a lower annualized relapse rate (0.20) compared to 
patients treated with interferon (0.33). Moreover, MRI find-
ings supported the clinical results. There was no difference 
with respect to progression of disability between the two 
groups. Risks include transient cardiac conduction changes 
as well as potentially severe viral infections [42].  
Cladribine 
  Cladribine (2-chlorodeoxyadenosine) is an adenosine 
deaminase-resistant purine nucleoside. Cladribine induces 
apoptosis of lymphocytes by increasing deoxynucleotides 
levels in these cells [46]. This immune cell depletion results 
in decrease of inflammation. Cladribine causes sustained 
reduction in CD4
+
 cells and CD8
+
 T cells and transient re-
duction in CD19+ B cells, without affecting other immune 
cells [43]. In a recent study by Giovannoni et al. [43] pa-
tients with RRMS were randomly assigned to three groups 
who received either 3.5 mg/kg or 5.25 mg/kg of cladribine or 
placebo. The patients who received either 3.5 mg/kg or 5.25 
mg/kg of cladribine had a significant lower annualized re-
lapse rate (0.14 and 0.15 respectively) compared to the pla-
cebo group (0.33). Moreover the cladribine group had a sig-
nificant reduction in MRI evidence of MS activity. Adverse 
effects included lymphopenia (21.6% in the 3.5 mg/kg group 
and 31.5% in the 5.25 mg/kg group vs. 1.8% in the placebo 
group), and herpes zoster (8 patients in the 3.5 mg/kg group 
and 12 patients in the 5.25 mg/kg groups vs. none in the pla-
cebo group. An initial FDA review did not result in an ap-
proval and additional data submission is underway. 
Laquinimod 
  Laquinimod is a derivative of immunomodulatory agent 
linomide (quinoline-3-carboxamide). Its target has not been 
identified yet. Studies have shown that laquinimod induces 
the release of TGF-beta and favors Th2 cytokine production. 
Preliminary studies have shown that laquinimod decreases 
MS disease activity without causing generalized immuno-
suppression [45]. Study completion and FDA application is 
expected in 2011. 
Fumarate 
  Fumarate (BG0012) is an immunomodulatory agent 
whose exact mechanism of action is unknown. Studies have 
shown that it activates the nuclear factor-E2-related factor 2 Multiple Sclerosis: Pathogenesis and Treatment  Current Neuropharmacology, 2011, Vol. 9, No. 3    415 
(Nrf2) transcriptional pathway [47]. A current phase II clini-
cal trial has shown that fumarate decreases the number of 
new gadolinium-enhancing lesions on MRI by 69% com-
pared to placebo (p<0.0001) [48].  
Teriflunomide  
  Teriflunomide is an active metabolite of leflunomide. It 
is currently approved for the treatment for rheumatoid arthri-
tis. Its mechanism of action consists on inhibiting dihydro-
orotate dehydrogenase, which is a rate limiting step in 
pyrimidine synthesis [49]. Other actions include suppression 
of pro-inflammatory cytokines, inhibition of tyrosine kinase 
activity and inhibition of interaction between APCs and T 
cells [49]. A phase II clinical trial showed a decrease on ac-
tive lesions in treated RRMS patients compared to placebo 
by 56% (p<0.001) [50].  
CONCLUSION 
  The unknown etiology, probable disease heterogeneity, 
and immune system complexity will continue to provide 
challenges for clinicians treating MS. To date there is no 
cure for MS, and medications which decrease immunologic 
functions may have significant risks. The short term efficacy 
and safety of newer agents is being explored however the 
long term risks of these agents, particularly when used in 
combination or succession will remain uncertain. Moreover, 
physicians are faced with the treating potentially pregnant 
woman and at times even children. MS is more common in 
young adults, and females are predominantly affected. Also, 
recent studies show that MS can occur in children. Up to 5% 
of patients diagnosed with MS in the United States per year 
are children [51]. The use of a national MS disease registry 
may assist with the better understanding of both efficacy and 
safety as the treatment options expand. Only after the etiol-
ogy of MS is better understood will more focused, effective, 
safe and permanent treatments arise. 
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